Can-Fite Biopharma Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.68next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Namodenoson Phase III HCC Interim Analysis | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly8.5MTarget: Sufficient liquidity to fund operations for at least 12 months
Annual Revenues Annually410KTarget: Expansion through upfront and milestone payments from regional licensing agreements
Research and Development Expenses Annually6.7MTarget: Disciplined execution of ongoing Phase III and Phase II clinical trials
Watch Items
- Namodenoson Phase III trial in advanced hepatocellular carcinoma (HCC)Trigger: Interim analysis data releaseAction: Evaluate eligibility to seek conditional regulatory approval from the FDA and EMA based on positive interim results
- Namodenoson Phase IIb trial in metabolic dysfunction-associated steatohepatitis (MASH)Trigger: Patient enrollment progress and clinical updatesAction: Monitor anti-inflammatory, anti-steatotic, and anti-fibrotic efficacy signals
- Piclidenoson Phase III trial in psoriasisTrigger: Patient enrollment milestones and primary efficacy endpoints (PASI 75 and PGA)Action: Assess clinical progress and prepare for regulatory submissions
- Vetbiolix Phase II canine osteoarthritis studyTrigger: Top-line results expected in Q3 2026Action: Review data to validate Piclidenoson's potential in the canine market and trigger potential milestone payments
Research as of 20 Jun 2026